Fortress Biotech 9.375% Series A Preferred Stock
FBIOP
1 hedge funds and large institutions have $1.16M invested in Fortress Biotech 9.375% Series A Preferred Stock in 2022 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0.38% less ownership
Funds ownership: 2.19% → 1.81% (-0.38%)
15% less capital invested
Capital invested by funds: $1.37M → $1.16M (-$205K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Shikiar Asset Management
New York
|
-$251K |
FBIOP Hedge Fund Activity: Q3 2022 in Review
1 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) for Q3 2022, worth a combined $1.16M — down 15% from $1.37M a quarter earlier.
Fund positioning in FBIOP was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Shikiar Asset Management, cutting an estimated $251K.
- 1 institutional investor held Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $1.16M of Fortress Biotech 9.375% Series A Preferred Stock stock for Q3 2022, down 15% quarter-over-quarter.
- 0 funds opened new Fortress Biotech 9.375% Series A Preferred Stock positions in Q3 2022 and 0 closed out.
- The largest Fortress Biotech 9.375% Series A Preferred Stock seller in Q3 2022 was Shikiar Asset Management, an estimated $251K sold.
Based on aggregated 13F filings for Q3 2022.